Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.

S, Minozzi; S, Bonovas; T, Lytras; V, Pecoraro; M, González-Lorenzo; AJ, Bastiampillai; EM, Gabrielli; AC, Lonati; L, Moja; M, Cinquini; V, Marino; A, Matucci; GM, Milano; G, Tocci; R, Scarpa; D, Goletti; F, Cantini

doi:10.1080/14740338.2016.1240783

Public

Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.

Shared by NobleBlocks on Dec 1, 2016 • 12:00 AM UTC

Authors:

Minozzi S

Bonovas S

Lytras T

Abstract

<h4>Introduction</h4>Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory approval for use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and etanercept. Apart from their well-documented therapeutic value, it is still uncertain to what extent they are associa...

Subject

Tuberculosis

Rheumatoid arthritis

Meta-analysis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!